854,973 Shares in Iovance Biotherapeutics, Inc. $IOVA Acquired by Deutsche Bank AG

Deutsche Bank AG acquired a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 854,973 shares of the biotechnology company’s stock, valued at approximately $3,557,000.

Several other large investors also recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its position in shares of Iovance Biotherapeutics by 161.2% in the first quarter. Royal Bank of Canada now owns 522,887 shares of the biotechnology company’s stock worth $1,740,000 after buying an additional 322,680 shares during the period. AQR Capital Management LLC raised its position in Iovance Biotherapeutics by 279.0% during the first quarter. AQR Capital Management LLC now owns 59,540 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 43,829 shares during the period. Goldman Sachs Group Inc. lifted its stake in Iovance Biotherapeutics by 30.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,571,902 shares of the biotechnology company’s stock worth $18,554,000 after acquiring an additional 1,301,846 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Iovance Biotherapeutics by 202.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock worth $19,239,000 after acquiring an additional 3,869,617 shares during the period. Finally, Envestnet Asset Management Inc. grew its stake in Iovance Biotherapeutics by 112.1% during the 2nd quarter. Envestnet Asset Management Inc. now owns 47,466 shares of the biotechnology company’s stock valued at $82,000 after acquiring an additional 25,083 shares in the last quarter. 77.03% of the stock is owned by institutional investors and hedge funds.

Iovance Biotherapeutics Stock Performance

Shares of IOVA opened at $8.08 on Thursday. The firm has a market cap of $3.66 billion, a PE ratio of -11.07 and a beta of 0.71. The firm’s 50 day moving average price is $5.30 and its 200 day moving average price is $4.25. Iovance Biotherapeutics, Inc. has a twelve month low of $1.76 and a twelve month high of $9.36.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The company had revenue of $198.63 million during the quarter, compared to the consensus estimate of $87.83 million. During the same period in the previous year, the firm posted ($0.33) earnings per share. The company’s revenue for the quarter was up 65.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Iovance Biotherapeutics, Inc. will post -0.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IOVA has been the topic of a number of research reports. Citigroup reiterated an “outperform” rating on shares of Iovance Biotherapeutics in a report on Friday, August 7th. Mizuho raised their price target on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “outperform” rating in a report on Tuesday, August 18th. UBS Group upped their price objective on shares of Iovance Biotherapeutics from $4.00 to $7.00 and gave the company a “neutral” rating in a research note on Thursday, August 20th. Citizens Jmp increased their target price on shares of Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. Finally, TD Cowen lifted their target price on shares of Iovance Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Monday. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.89.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical?stage biotechnology company specializing in the development and commercialization of tumor?infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN?144), is an autologous TIL therapy in late?stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next?generation TIL programs such as LN?145 for cervical and other human papillomavirus (HPV)?related cancers, as well as exploratory studies in head and neck, non?small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor?reactive lymphocytes.